27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
In the last three months, 6 analysts have published ratings on Amylyx Pharma (NASDAQ:AMLX), offering a diverse range of perspectives from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 4 | 0 | 2 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 2 | 0 | 2 | 0 | 0 |
| 2M Ago | 1 | 0 | 0 | 0 | 0 |
| 3M Ago | 0 | 0 | 0 | 0 | 0 |
Analysts have recently evaluated Amylyx Pharma and provided 12-month price targets. The average target is $10.67, accompanied by a high estimate of $32.00 and a low estimate of $4.00. Experiencing a 66.31% decline, the current average is now lower than the previous average price target of $31.67.
Deciphering Analyst Ratings: An In-Depth Analysis
The analysis of recent analyst actions sheds light on the perception of Amylyx Pharma by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Andrew Fein | HC Wainwright & Co. | Maintains | Buy | $8.00 | $8.00 |
| Andrew Fein | HC Wainwright & Co. | Lowers | Buy | $8.00 | $42.00 |
| Neena Bitritto-Garg | Deutsche Bank | Lowers | Buy | $8.00 | $36.00 |
| Chris Shibutani | Goldman Sachs | Lowers | Neutral | $4.00 | $40.00 |
| Joel Beatty | Baird | Lowers | Neutral | $4.00 | $37.00 |
| Graig Suvannavejh | Mizuho | Raises | Buy | $32.00 | $27.00 |
Key Insights:
- Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Amylyx Pharma. This offers insight into analysts' perspectives on the current state of the company.
- Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Amylyx Pharma compared to the broader market.
- Price Targets: Gaining insights, analysts provide estimates for the future value of Amylyx Pharma's stock. This comparison reveals trends in analysts' expectations over time.
Capture valuable insights into Amylyx Pharma's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
Stay up to date on Amylyx Pharma analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
Discovering Amylyx Pharma: A Closer Look
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. It has one operating segment which is the business of researching and developing therapeutics for neurodegenerative disorder.
Amylyx Pharma: A Financial Overview
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Amylyx Pharma's remarkable performance in 3 months is evident. As of 31 December, 2023, the company achieved an impressive revenue growth rate of 395.54%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Amylyx Pharma's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 4.36% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Amylyx Pharma's ROE stands out, surpassing industry averages. With an impressive ROE of 1.11%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Amylyx Pharma's ROA stands out, surpassing industry averages. With an impressive ROA of 0.96%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: With a below-average debt-to-equity ratio of 0.01, Amylyx Pharma adopts a prudent financial strategy, indicating a balanced approach to debt management.
Analyst Ratings: What Are They?
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!